EF Hutton Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Tim Moore maintains a Buy rating on Sonnet BioTherapeutics (NASDAQ:SONN) but lowers the price target from $11 to $7.
May 16, 2024 | 6:24 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
EF Hutton analyst Tim Moore maintains a Buy rating on Sonnet BioTherapeutics but lowers the price target from $11 to $7.
The Buy rating suggests continued confidence in the company's prospects, but the lowered price target indicates tempered expectations for short-term performance. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100